Somatostatin CAS:51110-01-1

Somatostatin (also known as incrementum hormone-inhibendo hormone (GHIH) aut somatotropin emissio-inhibentes factor (SRIF)) vel somatotropinum emissio hormona inhibita est peptide hormona quae systema endocrinum moderatur et afficit neurotransmissionem et proliferation cellularum per commercium cum receptoribus G dapibus-iunctatum somatostatin et inhibitio remissionis plurium hormonum secundariorum.. Somatostatin moderatur insulinum et glucagon.

Somatostatin duas formas activas productas per alterius unius preproprotein fissuram: unus of * 14 amino acida, alter of * 28 amino acida.

In omnibus vertebrates, sex inveniuntur genes somatostatin nominatae SS1, SS2, SS3, SS4, SS5, et SS6 ". The six different genes along with the five different somatostatin receptors allows somatostatin to possess a large range of functions. Humans have only one somatostatin gene, SST.

It can inhibit , thyroid stimulating hormone, the secretion of insulin, glucagon's. can inhibit secretion by the test meal and five pentagastrin stimulated gastric acid, pepsin and inhibit the release of gastrin. splanchnic blood flow can be significantly reduced, reducing portal pressure, reduced blood flow and pressure of collateral circulation, reduced hepatic blood flow. reduce gallbladder and pancreatic secretion of gastric secretion and outside of the small intestine, reducing the activity of pancreatic cells have a protective effect. inhibition of glucagon secretion. can affect the gastrointestinal absorption and nutritional function.

una immunditia (HPLC) 1.0%max
Amino Acidum Compositionem ± 10% theoretical
Peptide Content (N%) ≥ 80.0%
Aqua Content (Carolus Fischer) ≤ 8.0%
Acetate Content (HPIC)≤ 15.0%
MS (ESI)Congruunt
Imprimis Rotationes (20/D) -37.0~-47.0° (c = 1 1% HAc)
Missa Libra 95.0~ 105.0%